Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everest 2: Cetuximab Dose Escalation in KRAS WT mCRC
NCT01251536Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- Dec 2010
- Primary completion
- Jun 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, open-label trial of cetuximab in metastatic colorectal cancer (mCRC) (2 arms), sponsored by UZ Leuven. Primary endpoint: Progression Free Survival Probability Rate at 9 Months in the Dose Escalation Arm. Started Dec 2010; status: completed.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01251536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01251536.